What does MapLight Therapeutics, Inc. do?
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease…
What is MapLight Therapeutics, Inc.'s P/E and P/B ratio?
MapLight Therapeutics, Inc. has a P/E ratio of -1.3 and a P/B ratio of 1.32.
What is MapLight Therapeutics, Inc.'s debt-to-equity ratio?
MapLight Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does MapLight Therapeutics, Inc. owe compared with what it owns?
MapLight Therapeutics, Inc. owes $0.05 for every $1 it owns (balance sheet Jun 2026), which is low.
What is MapLight Therapeutics, Inc.'s Positivity rank?
MapLight Therapeutics, Inc. is ranked #429 of 6,774 companies globally and #65 of 4,000 in United States on PositoAI, with a Positivity Score of 24,402.
Does MapLight Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for MapLight Therapeutics, Inc..
Where can I read the latest news about MapLight Therapeutics, Inc.?
Recent headlines about MapLight Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does MapLight Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of MapLight Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.